Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13850111 | 0.91 | SIGMAR1 (0.47) | SIGMAR1TRPV6CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17304911 | 0.83 | SIGMAR1 (0.45) | SIGMAR1TRPV6CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4623772 | 0.77 | CXCR4 (0.53) | SIGMAR1TRPV6CXCR3CYP2D6CYP2C9 | |
| SCHEMBL23198133 | 0.77 | TRPV6 (0.52) | SIGMAR1TRPV6CXCR3CYP2D6CYP2C9 | |
| SCHEMBL14375212 | 0.77 | ACHE (0.54) | SIGMAR1TRPV6CXCR3CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL4887046 | 0.76 | CXCR4 (0.51) | SIGMAR1TRPV6CXCR3CYP2D6CYP2C9 | |
| SCHEMBL13176517 | 0.75 | SIGMAR1 (0.47) | SIGMAR1TRPV6CYP2C19ALDH1A1LMNA | |
| SCHEMBL13375739 | 0.74 | TRPV6 (0.50) | SIGMAR1TRPV6CXCR3CYP2D6CYP2C9 | |
| SCHEMBL31670698 | 0.73 | SIGMAR1 (0.55) | SIGMAR1TRPV6CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8045561 | 0.73 | SIGMAR1 (0.55) | SIGMAR1TRPV6CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | SIGMAR1 2301/4885TRPV6 4285/4885CXCR3 3286/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | SIGMAR1 2301/4885TRPV6 4285/4885CXCR3 3286/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | SIGMAR1 2301/4885TRPV6 4285/4885CXCR3 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.